Axogen Gestione
Criteri Gestione verificati 4/4
Axogen Il CEO è Mike Dale, nominato in Aug2024, e ha un mandato di 2.08 anni. la retribuzione annua totale è $ 9.05M, composta da 8.6% di stipendio e 91.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di $ 2.81M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 4.2 anni.
Informazioni chiave
Mike Dale
Amministratore delegato
US$9.0m
Compenso totale
| Percentuale dello stipendio del CEO | 8.58% |
| Mandato del CEO | 2.1yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 2.1yrs |
| Durata media del Consiglio di amministrazione | 4.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Aug 04
AXGN: Raised 2026 Guidance And Q2 Execution Will Support Further Upside
Axogen's updated analyst price target has increased from $50.78 to $53.22 as analysts respond to stronger Q2 results, higher revenue and margin assumptions, and a lower projected P/E multiple. Together, these factors support a modestly higher valuation.Seeking Alpha • Aug 03
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
Summary Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance’s FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity. AXGN trades at a premium valuation, requiring sustained 15-20%+ growth and operating leverage; execution, margin expansion, and confirmatory trial results are critical to justifying current multiples. Read the full article on Seeking AlphaArticolo di analisi • Aug 01
Analysts Have Made A Financial Statement On Axogen, Inc.'s (NASDAQ:AXGN) Second-Quarter Report
Investors in Axogen, Inc. ( NASDAQ:AXGN ) had a good week, as its shares rose 6.9% to close at US$42.21 following the...Aggiornamento narrativa • Jun 14
AXGN: Lower Discount Rate And 2026 Guidance Will Support Further Upside
Axogen's analyst price target has been raised in a series of Street updates, with increases such as $5, $7, $8, $10 and $11, as analysts point to refined discount rate and earnings assumptions while keeping fair value and long term growth forecasts broadly consistent. Analyst Commentary Recent Street research on Axogen clusters around a similar narrative, with price target changes framed around adjustments to discount rates and earnings assumptions rather than sweeping changes to long term growth views or fair value frameworks.Aggiornamento narrativa • May 31
AXGN: Lower Risk Assumptions And 2026 Guidance Will Drive Upside Potential
Axogen's updated analyst price target is unchanged in this model at $50.78. Recent target increases from multiple firms are generally tied by analysts to refined discount rate assumptions and updated long term P/E expectations, rather than shifts in projected revenue growth or profit margins.Aggiornamento narrativa • May 04
AXGN: BLA Approval And New Market Entry Will Drive Upside Potential
Axogen's analyst price target has been raised from $41.22 to $50.78, with analysts pointing to updated assumptions around fair value, revenue growth, profit margins and recent Street research highlighting the impact of Avance Nerve Graft's BLA approval and commercial expansion opportunities. Analyst Commentary Recent Street research around Axogen clusters around the impact of Avance Nerve Graft's BLA approval, expanded market exposure and revised fair value assumptions, with a series of price target moves anchoring the discussion.Articolo di analisi • Apr 30
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78
It's been a pretty great week for Axogen, Inc. ( NASDAQ:AXGN ) shareholders, with its shares surging 12% to US$41.77 in...Aggiornamento narrativa • Apr 18
AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook
Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.Aggiornamento narrativa • Apr 01
AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption
Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.Aggiornamento narrativa • Mar 17
AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption
Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.Aggiornamento narrativa • Mar 03
AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout
Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.Aggiornamento narrativa • Feb 17
AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook
Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.Aggiornamento narrativa • Feb 02
AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook
Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.Aggiornamento narrativa • Jan 19
AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence
Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.Aggiornamento narrativa • Jan 04
AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook
Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.Aggiornamento narrativa • Dec 14
AXGN: Market Development Progress Will Support Confidence In 2025 Outlook
Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.Aggiornamento narrativa • Nov 30
AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead
Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.Articolo di analisi • Nov 27
Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Aggiornamento narrativa • Nov 16
AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook
Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.Articolo di analisi • Nov 04
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shares have continued their recent momentum with a 30% gain in the last month alone. The...Aggiornamento narrativa • Oct 31
AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside
Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.Articolo di analisi • Sep 12
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jul 23
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Those holding Axogen, Inc. ( NASDAQ:AXGN ) shares would be relieved that the share price has rebounded 29% in the last...Nuova narrativa • May 29
BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.Articolo di analisi • May 10
Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
Axogen, Inc. ( NASDAQ:AXGN ) shareholders that were waiting for something to happen have been dealt a blow with a 32...Articolo di analisi • Apr 17
Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Mar 26
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Axogen, Inc. ( NASDAQ:AXGN ) is a stock to...Articolo di analisi • Jan 14
Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$34m |
| Mar 31 2026 | n/a | n/a | -US$31m |
| Dec 31 2025 | US$9m | US$776k | -US$16m |
| Sep 30 2025 | n/a | n/a | -US$2m |
| Jun 30 2025 | n/a | n/a | -US$5m |
| Mar 31 2025 | n/a | n/a | -US$7m |
| Dec 31 2024 | US$9m | US$303k | -US$10m |
Compensazione vs Mercato: La retribuzione totale di Mike ($USD 9.05M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 7.02M ).
Compensazione vs guadagni: La retribuzione di Mike è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Mike Dale (66 yo)
2.1yrs
Mandato
US$9,047,454
Compensazione
Mr. Michael D. Dale is Independent Director of CVRx, Inc. from June 1, 2026. Mr. Dale is CEO & Director of AxoGen, Inc. from August 9, 2024 and also serves as its President since 2025. Mr. Dale served as t...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.1yrs | US$9.05m | 0.11% $ 2.8m | |
| Chief Financial Officer | 1.3yrs | US$1.94m | 0.11% $ 2.9m | |
| Chief Scientific Officer | less than a year | US$2.26m | 0.41% $ 10.5m | |
| Executive VP | 3.5yrs | US$3.06m | 0.085% $ 2.2m | |
| Chief Marketing Officer | 3.6yrs | US$2.28m | 0.12% $ 3.2m | |
| Senior Vice President of Operations | no data | Nessun dato | Nessun dato | |
| Vice President of Finance & Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Medical Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Chief Revenue Officer | less than a year | Nessun dato | 0.16% $ 4.1m | |
| Vice President of Global Health Economics | no data | Nessun dato | Nessun dato |
2.1yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di AXGN è considerato esperto (durata media dell'incarico 2.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.1yrs | US$9.05m | 0.11% $ 2.8m | |
| Independent Chairman of the Board | 6yrs | US$242.06k | 0.055% $ 1.4m | |
| Member of Board of Advisor | no data | Nessun dato | Nessun dato | |
| Member of Board of Advisor | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.2yrs | US$217.49k | 0.024% $ 625.9k | |
| Independent Director | 2.8yrs | US$212.66k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$217.49k | 0.087% $ 2.3m | |
| Independent Director | 4.2yrs | US$224.99k | 0.024% $ 630.3k | |
| Independent Director | 3.8yrs | US$209.99k | 0.018% $ 471.0k |
4.2yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AXGN sono considerati esperti (durata media dell'incarico 4.2 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 11:54 |
| Prezzo dell'azione a fine giornata | 2026/09/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Axogen, Inc. è coperta da 19 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Christopher Pasquale | Guggenheim Securities, LLC |